OakChart

Achieve Life Sciences Inc

QUITHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

6.45+0.05 (0.78%)
2026-11-12 03:47 CET
Market cap
663.72 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-111.71 USD m
Free cash flow, TTM
-44.09 USD m
EPS diluted, TTM
-1.38
P/E
-
Compare

Price

QUIT against its 20, 50 and 200-day averages
2050200beatmiss
4.006.008.006.2M12.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26QUITclose 6.4520-day 6.6750-day 7.22200-day 5.696.4552w high

25.3% under the 52-week high of 8.64 on 3 Sep 2026. 52-week low 2.62 on 30 Mar 2026. Last 15 sessions, 19.3% high to low

Volume 0.78× normal · the line is the 50-bar volume average

Profile

QUIT
52-week range, 64% of the way up
2.628.64

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.

IndexRUT
Employees28
IPOOct 12, 1995
Beta2.41
ATR, 14d0.44
Rel volume0.78
Short float25.97%
Insider own32.16%
Inst own57.17%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap663.73M
Enterprise Value476.26M
Income-111.71M
Sales0.00M
Book/sh1.65
Cash/sh1.96
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees28
IPOOct 12, 1995

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.92
P/C3.29
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio10.49
Current Ratio10.49
Debt/Eq0.08
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.38
EPS next Y-0.69
EPS next Q-0.21
EPS this Y-13.34%
EPS next Y51.13%
EPS next 5Y-
EPS past 3/5Y32.06% 25.38%
Sales past 3/5Y- -
EPS Y/Y TTM-0.17%
Sales Y/Y TTM-
EPS Q/Q59.45%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.44.92% -

Ownership

Insider Own32.16%
Insider Trans-0.06%
Inst Own57.17%
Inst Trans49.05%
ROA-86.44%
ROE-104.23%
ROIC-59.73%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-3.26%
SMA50-10.62%
SMA20013.35%
Trades-

Technical

Shs Outstand109.78M
Shs Float69.81M
Short Float25.97%
Short Ratio12.26
Short Interest18.13M
52W High8.64 -25.35%
52W Low2.62 146.18%
Volatility8.23% 6.47%
ATR (14)0.44
RSI (14)43.21
Beta2.41
Rel Volume0.78
Avg Volume1.48M
Volume1,155,606

Performance

Perf Week-7.59%
Perf Month-7.86%
Perf Quarter-11.03%
Perf Half Y8.22%
Perf YTD29.78%
Perf Year35.22%
Perf 3Y56.93%
Perf 5Y-22.48%
Perf 10Y-99.27%
Recom1.00
Target Price14.58
Prev Close6.40
Price6.45
Change %0.78%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Sep 30, 2026InitiatedSStifelBuy$18+179.1%
Aug 13, 2026InitiatedMMorgan StanleyOverweight$13+101.6%
Jun 26, 2026ResumedRRaymond JamesStrong Buy$20+210.1%
Apr 21, 2026InitiatedCCanaccord GenuityBuy$13+101.6%
Nov 25, 2025InitiatedCCitizens JMPMkt Outperform$19+194.6%
Aug 21, 2025InitiatedHH.C. WainwrightBuy$12+86.0%
Nov 14, 2024InitiatedRRodman & RenshawBuy$12+86.0%
Sep 27, 2024InitiatedRRaymond JamesStrong Buy$20+210.1%
May 10, 2023ReiteratedMMaxim GroupBuy$8 → $20+210.1%
Jun 23, 2021InitiatedOOppenheimerOutperform$23+256.6%

Peers

Mkt cap
TickerCompanyMkt cap
AXSMAxsome Therapeutics Inc7.85B
AZRAzora Therapeutics Inc49.99M
PHATPhathom Pharmaceuticals Inc510.51M
VNDAVanda Pharmaceuticals Inc250.95M
ACOGAlpha Cognition Inc187.72M
RLMDRelmada Therapeutics Inc472.55M
TNXPTonix Pharmaceuticals Holding Corp75.20M
HELPHelus Pharma Inc686.03M
CINGCingulate Inc67.47M
MNOVMedicinova Inc69.40M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Stewart Richard AlistairDirectorAug 19 '26Sale8.4920,626175,177208,249Aug 21 04:30 PM
Stewart Richard AlistairDirectorAug 19 '26Proposed Sale7.5220,626155,108Aug 19 09:16 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SURISimplify Propel Opportunities ETFAUM: 74.30M
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWCiShares Micro-Cap ETFAUM: 1.22B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.82B

News

latest 14 of 100
  • Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT (GlobeNewswire)
  • Achieve Life Sciences Announces Granting of New Hire Inducement Awards (GlobeNewswire)
  • Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026 (GlobeNewswire)
  • Lisata adds biopharma finance veteran Jeffrey Farrow to board (Proactive)
  • Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications (GlobeNewswire)
  • Achieve Life Sciences Announces Granting of New Hire Inducement Awards (GlobeNewswire)
  • Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer (GlobeNewswire) -6.92%
  • Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 (GlobeNewswire)
  • Achieve Life Sciences Announced Granting of New Hire Inducement Awards (GlobeNewswire)
  • Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality (GlobeNewswire)
  • Achieve Life Sciences Announced Granting of New Hire Inducement Awards (GlobeNewswire)
  • Achieve Life Sciences Joins Russell 2000 Index (GlobeNewswire)
  • Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA (GlobeNewswire) +5.15%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.110-0.200-0.1100.000.0012
2026Q22026-08-11-0.800-0.165-0.8000.000.0011
2026Q12026-05-12-0.190-0.299-0.1910.000.007
2025Q42026-03-24-0.280-0.288-0.2750.000.005
2025Q32025-11-06-0.280-0.244-0.2830.000.005
2025Q22025-08-07-0.370-0.366-0.3670.000.005
2025Q12025-05-13-0.370-0.382-0.3700.000.006
2024Q42025-03-11-0.360-0.341-0.3580.000.008
2024Q32024-11-07-0.360-0.272-0.3640.000.006
2024Q22024-08-13-0.250-0.239-0.2470.000.007
2024Q12024-05-09-0.260-0.242-0.2590.000.006
2023Q42024-03-28-0.260-0.310-0.2590.000.006
2023Q32023-11-09-0.340-0.368-0.3360.000.005
2023Q22023-08-14-0.430-0.408-0.4330.000.006
2023Q12023-05-09-0.500-0.686-0.5020.000.005
2022Q42023-03-16-0.830-0.947-0.8300.000.136

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-39.800-25.200-39.7630.000.00
2020FY-5.420-5.213-5.4180.000.00
2021FY-4.080-3.920-4.0830.000.04
2022FY-4.000-4.065-3.9980.000.10
2023FY-1.500-1.562-1.5040.000.00
2024FY-1.240-1.221-1.2420.000.00
2025FY-1.250-1.276-1.2500.000.00
2026FY--1.417--0.00
2027FY--0.692--34.94
2028FY-0.155--135.21
2029FY-1.170--296.51
2030FY-2.170--460.79

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-107000.000.000.00
2026Q4S2026-08-117000.000.000.00
2026Q4S2026-05-296000.000.000.00
2026Q4S2026-05-156010.000.000.00
2026Q4S2026-05-125010.000.000.00
2026Q4S2026-04-145010.000.000.00
2026Q4S2026-03-244000.000.000.00
2026Q4S2025-12-1110017.7517.7517.75
2026Q4S2025-11-1120014.8712.0017.75
2026Q4S2025-11-1020014.8712.0017.75
2026Q4R2026-11-101231-0.21-0.36-0.10
2026Q4R2026-10-271201-0.21-0.36-0.10
2026Q4R2026-10-261203-0.21-0.36-0.10
2026Q4R2026-10-251204-0.21-0.36-0.10

Estimate history

EPS, annual-442-72.286-39.763-5.418-4.083-3.998-1.504-1.242-1.254-1.3801
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.364-0.358-0.37-0.367-0.283-0.275-0.191-0.8-0.115
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.060.3361.4746.1129.45417.89721.16634.68553.234109.777
Period201720182019202020212022202320242025MRQ
Shares, quarterly34.3934.68534.68549.68552.81253.23453.241102.717109.777
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.230.230.230.230.240.250.260.250.28
Gross Profit-0.23-0.23-0.23-0.23-0.24-0.25-0.26-0.25-0.28
Selling, General and Administrative Excl. Other63.8954.6538.8427.0240.5632.8414.4916.2712.53
Research and Development17.1923.0022.8215.8130.0823.976.889.675.87
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-64.12-54.88-39.07-27.25-40.80-33.09-14.75-16.53-12.81
Interest Expense1.060.822.182.851.79-0.000.00-
Unusual Expense50.490.410.900.530.000.000.000.000.00
Net Income Before Taxes-111.71-54.65-39.83-29.82-42.35-33.15-14.73-16.39-12.69
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-111.71-54.65-39.83-29.82-42.35-33.15-14.73-16.39-12.69
Net Income From Continuing Operations-111.71-54.65-39.83-29.82-42.35-33.15-14.73-16.39-12.69
Net Income-111.71-54.65-39.83-29.82-42.35-33.15-14.73-16.39-12.69
EPS (Recurring)-0.72-1.25-1.22-1.49-4.00-4.08-5.42-39.76-72.29
EPS (Basic, Before Extraordinaries)-1.38-1.25-1.24-1.50-4.00-4.08-5.42-39.76-72.29
EPS (Diluted)-1.38-1.25-1.24-1.50-4.00-4.08-5.42-39.76-72.29
EBITDA-63.89-54.65-38.84-27.02-40.56-32.84-14.49-16.27-12.53
Non-Operating Income (Expense)3.961.462.330.820.24-0.060.020.130.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.288.765.333.443.272.191.291.200.67
Shares Outstanding109.7853.2334.6921.1717.909.456.111.470.34
Market Capitalization663.72663.72121.0587.2023.7973.5529.3015.628.13

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.060.060.060.060.050.060.060.06
Gross Profit-0.06-0.06-0.06-0.06-0.05-0.06-0.06-0.06
Selling, General and Administrative Excl. Other20.4718.3310.4114.6714.6412.5112.8312.13
Research and Development6.213.813.293.875.326.717.107.30
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-20.54-18.39-10.46-14.73-14.69-12.56-12.89-12.19
Interest Expense0.260.280.270.250.190.190.180.20
Unusual Expense-6.9157.57-0.280.110.110.100.090.45
Net Income Before Taxes-12.11-74.77-10.17-14.66-14.44-12.72-12.83-12.36
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-12.11-74.77-10.17-14.66-14.44-12.72-12.83-12.36
Net Income From Continuing Operations-12.11-74.77-10.17-14.66-14.44-12.72-12.83-12.36
Net Income-12.11-74.77-10.17-14.66-14.44-12.72-12.83-12.36
EPS (Recurring)-0.16-0.37-0.19-0.27-0.28-0.36-0.37-0.35
EPS (Basic, Before Extraordinaries)-0.11-0.80-0.19-0.28-0.28-0.37-0.37-0.36
EPS (Diluted)-0.11-0.80-0.19-0.28-0.28-0.37-0.37-0.36
EBITDA-20.47-18.33-10.41-14.67-14.64-12.51-12.83-12.13
Non-Operating Income (Expense)1.771.470.280.430.550.130.340.48
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.706.96-0.691.302.342.892.231.24
Shares Outstanding109.78102.7253.2453.2352.8149.6934.6934.69
Market Capitalization663.72670.36156.53264.57160.9878.3992.61121.05

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments36.4034.3615.5524.7743.0235.8516.6614.605.51
Short Term Receivables0.000.000.110.100.150.000.010.010.01
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.482.111.322.451.421.120.660.930.39
Total Current Assets39.8936.4716.9827.3344.5936.9817.3315.545.91
Net Property, Plant & Equipment0.070.130.080.130.080.190.390.040.06
Total Investments and Advances0.020.020.050.050.050.050.050.050.05
Intangible Assets1.782.012.232.452.672.903.123.343.57
Deferred Tax Assets0.28--------
Other Assets0.030.010.030.010.120.190.190.120.31
Total Assets42.0738.6319.3729.9747.5240.3021.0819.089.89
Short Term Debt Incl. Current Port. of LT Debt3.770.0616.7316.130.070.090.200.010.03
Accounts Payable0.871.950.621.660.840.330.860.140.21
Other Current Liabilities4.454.683.473.813.642.511.813.121.77
Total Current Liabilities9.086.6820.8121.604.552.942.873.272.01
Long Term Debt11.199.900.010.0714.920.080.160.010.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.28--------
Other Liabilities0.001.150.000.000.000.000.000.000.00
Total Liabilities20.5517.7320.8221.6719.473.013.033.282.01
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity21.5220.90-1.458.3028.0437.2918.0515.807.88
Total Shareholders Equity21.5220.90-1.458.3028.0437.2918.0515.807.88
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity21.5220.90-1.458.3028.0437.2918.0515.807.88
Total Liabilities & Stockholders Equity42.0738.6319.3729.9747.5240.3021.0819.089.89
Book Value Per Share0.400.60-0.070.462.976.1012.2447.02131.89
Tangible Book Value Per Share0.370.54-0.170.332.685.6310.1337.0772.20
Full-Time Employees282522201613141313
Price to Book Ratio3.923.8621.6022.792.621.330.870.511.44
Return on Assets-135.42-137.33-120.85-109.31-75.51-48.00-81.64-87.57-56.65
Return on Equity-257.67-409.51-869.88-233.04-101.49-53.24-96.86-107.15-78.85
Return on Invested Capital-167.08-129.30--505.85-77.16-39.42-90.04-80.23-134.32
Quick Ratio4.395.460.821.279.8012.606.044.752.93
Current Ratio4.395.460.821.279.8012.606.044.752.93

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-111.71-54.65-39.83-29.82-42.35-33.15-14.73-16.39-12.69
Depreciation0.230.230.230.230.240.250.260.250.28
Other Funds (Non Cash)64.179.227.425.894.452.231.291.200.85
Funds from Operations-47.30-45.20-32.18-23.70-37.67-30.67-13.19-14.94-11.55
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.26-4.272.41-0.780.101.23-0.28-0.270.93
Cash from Operating Activities-44.04-49.47-29.77-24.48-37.57-29.44-13.47-15.22-10.62
Capital Expenditures-0.22-0.000.00-0.020.000.00-0.02-0.05-0.05
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.01
Purchase or Sale of Investments-124.266.11-21.580.000.000.000.005.09-5.09
Purchase of Investments-177.77-24.75-47.890.000.000.000.00-0.03-5.54
Sale Or Maturity of Investments53.5230.8726.310.000.000.000.005.110.45
Other Uses-0.00-0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-124.486.11-21.58-0.020.000.00-0.025.04-5.12
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock193.2046.5356.9415.5019.3621.6832.6817.3219.76
Repurchase of Common Pref Stock0.000.000.00-0.030.000.000.000.000.00
Sale of Common Pref Stock193.2046.5356.9415.5319.3621.6832.6817.3219.76
Proceedsfrom Stock Options172.4145.140.0015.3019.3421.3429.5013.1318.43
Issuance or Reduction of Debt, Net3.125.00-8.290.000.0014.930.000.000.00
Change in Long Term Debt3.125.00-8.290.000.0014.930.000.000.00
Issuance of Long Term Debt5.005.009.810.000.0014.930.000.000.00
Reduction of Long Term Debt-1.880.00-18.110.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.11-0.22-0.050.000.000.000.00
Other Financing Activities Uses0.000.00-0.11-0.22-0.050.000.000.000.00
Cash from Financing Activities196.3251.5348.5315.2819.3236.6132.6817.3219.76
Exchange Rate Effect0.000.000.00-0.000.00-0.000.000.000.00
Net Change in Cash27.818.18-2.82-9.22-18.257.1719.197.154.01
Free Cash Flow-44.09-49.47-29.77-24.50-37.57-29.44-13.49-15.27-10.67
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments201.52187.3029.2736.4048.1155.40
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.890.991.793.481.941.51
Total Current Assets203.41188.2931.0639.8950.0556.90
Net Property, Plant & Equipment0.970.030.050.070.080.09
Total Investments and Advances0.020.230.230.020.020.02
Intangible Assets1.781.841.731.781.841.90
Deferred Tax Assets---0.28--
Other Assets0.230.030.030.030.040.02
Total Assets206.42190.4433.1042.0752.0458.94
Short Term Debt Incl. Current Port. of LT Debt7.747.495.633.771.261.27
Accounts Payable1.600.610.830.871.941.22
Other Current Liabilities10.05189.565.374.456.526.09
Total Current Liabilities19.39197.6611.839.089.738.57
Long Term Debt6.317.469.3211.198.708.69
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.28--
Other Liabilities0.000.001.270.000.000.00
Total Liabilities25.69205.1222.4320.5518.4317.27
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity180.73-14.6810.6821.5233.6241.67
Total Shareholders Equity180.73-14.6810.6821.5233.6241.67
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity180.73-14.6810.6821.5233.6241.67
Total Liabilities & Stockholders Equity206.42190.4433.1042.0752.0458.94
Book Value Per Share1.65-0.140.200.400.640.84
Tangible Book Value Per Share1.63-0.160.170.370.600.80
Full-Time Employees---28--
Price to Book Ratio3.9232.567.277.813.767.63
Return on Assets-86.44-91.46-171.97-135.42-104.74-81.50
Return on Equity-104.23-844.99-496.15-257.67-161.08-120.11
Return on Invested Capital-6.47--50.84-44.83-34.13-25.25
Quick Ratio10.490.952.624.395.146.64
Current Ratio10.490.952.624.395.146.64

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-12.11-74.77-10.17-14.66-14.44-12.72
Depreciation0.060.060.060.060.050.06
Other Funds (Non Cash)-0.1663.86-0.961.432.463.00
Funds from Operations-12.21-10.85-11.07-13.18-11.93-9.66
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital3.850.074.14-4.800.600.59
Cash from Operating Activities-8.36-10.78-6.93-17.98-11.33-9.07
Capital Expenditures-0.03-0.190.00-0.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-1.62-137.6214.280.71-12.656.70
Purchase of Investments-32.71-138.82-1.16-5.09-15.40-0.90
Sale Or Maturity of Investments31.081.2015.435.802.757.60
Other Uses0.000.000.00-0.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.66-137.8014.280.71-12.656.70
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock23.46168.460.021.264.0441.22
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock23.46168.460.021.264.0441.22
Proceedsfrom Stock Options-0.06168.460.004.00-0.0841.22
Issuance or Reduction of Debt, Net-1.880.000.005.000.000.00
Change in Long Term Debt-1.880.000.005.000.000.00
Issuance of Long Term Debt0.000.000.005.000.000.00
Reduction of Long Term Debt-1.880.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities21.58168.460.026.264.0441.22
Exchange Rate Effect-0.000.00-0.000.00--
Net Change in Cash11.5619.887.36-11.00-19.9438.86
Free Cash Flow-8.39-10.79-6.93-17.98-11.33-9.07

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3025.97%18.1M69.8M1.45M
2026-10-1525.51%17.8M69.8M1.40M
2026-09-3025.03%17.5M69.8M1.50M
2026-09-1522.91%16.0M69.8M1.85M
2026-08-3123.59%16.4M69.7M1.79M
2026-08-1423.66%16.4M69.4M1.80M
2026-07-3121.18%16.3M76.8M1.80M
2026-07-1519.17%14.7M76.8M2.09M
2026-06-3015.83%12.6M79.5M1.87M
2026-06-1510.35%8.2M79.5M1.42M
2026-05-299.66%7.7M79.5M1.26M
2026-05-159.81%7.2M73.8M1.11M
2026-04-308.54%6.9M80.7M975.12K
2026-04-1514.69%6.8M46.6M682.82K
2026-03-3115.28%7.1M46.6M677.96K
2026-03-1315.05%7.0M46.6M587.00K
2026-02-2714.44%6.7M46.6M616.63K
2026-02-1314.51%6.8M46.6M661.89K
2026-01-3014.64%6.8M46.6M704.49K
2026-01-1514.64%6.8M46.6M1.20M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.502.155.700.0016.6731.000.000.919-0.0890.002
call5.000.002.350.004.36450.000.000.763-0.0800.003
call7.500.150.950.003.3022420.000.486-0.0750.004
call10.000.000.050.00-2180.00---
call12.500.001.900.002.3910.000.000.056-0.0150.001
put2.500.001.900.0010.4430.000.00-0.081-0.0890.002
put5.000.000.950.004.5411510.00-0.237-0.0790.003
put7.500.601.750.002.69350.000.00-0.514-0.0740.004
put10.001.805.500.007.2190.000.00-0.929-0.0120.001
put12.504.308.000.008.1400.000.00-0.944-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-063Initial statement of beneficial ownership of securities2026-10-05SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17SCHEDULE 13GSEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14424B5SEC
2026-08-13SCHEDULE 13GSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-27SCHEDULE 13GSEC
2026-07-08SCHEDULE 13GSEC
2026-07-068-KCurrent report2026-07-02SEC
2026-06-08ARSAnnual report to security holders. 2025-12-31SEC
2026-06-08DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-08SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-023Initial statement of beneficial ownership of securities2026-05-29SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-023Initial statement of beneficial ownership of securities2026-05-29SEC
2026-06-028-KCurrent report2026-05-29SEC
2026-05-29PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800175.18K1
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
-

Funds

Fund% owned
-

OakChart. QUIT. Cached 15 minutes.